Warhound Secures $200M to Engineer Genetically Enhanced Military Dogs

The company, valued at $1.2 billion, is a collaboration between Colossal Biosciences CEO Ben Lamm and Anduril founder Palmer Luckey. Currently, over 80% of U.S. military working dogs are imported from Europe, with a high failure rate during training due to genetic predispositions for health issues like hip dysplasia and muscle atrophy. By utilizing gene-editing technology, Warhound intends to produce dogs with superior agility, enhanced olfactory sensors, and increased longevity.

Anduril will contribute hardware and software to the initiative, integrating sensors into protective vests and goggles to provide handlers with real-time situational awareness. The cloning process, managed in partnership with Viagen, is already underway, with the first litter expected early next year. Lamm anticipates these animals could enter active service within two years. To oversee the ethical implications of these enhancements, the company is coordinating with the American Humane Society to certify its training programs and ensure that retired dogs are integrated into established adoption pathways.